RecruitingEarly Phase 1NCT05283382

Cannabidiol Effects on Learning and Anxiety


Sponsor

University of Connecticut

Enrollment

160 participants

Start Date

Oct 30, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

To examine the extent to which Cannabidiol (CBD) enhances fear conditioning extinction in college undergraduates who show elevated social anxiety. Undergraduates who display elevated social anxiety on standard assessments will be recruited at the University of Connecticut. All participants will be put in a standard fear conditioning paradigm where they are conditioned to fear a face that occasionally is followed by a shock to their wrist. The other face never is paired with a shock. After everybody learns this, half of the participants will receive 600 mg CBD Isolate Gel Capsules one time, and the other half will receive a placebo dose. Participants will then be presented with the faces with no shocks, and the rate and duration of extinction as measured by electrodermal response as well as subjective fear ratings via a visual analogue scale will be examined. It is hypothesized that participants that receive CBD will display enhanced extinction compared to the placebo group, as evidenced by reduced electrodermal response and reduced visual analogue fear ratings.


Eligibility

Min Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This study investigates how CBD (cannabidiol) affects learning and anxiety. Participants complete computer-based learning and memory tasks before and after taking CBD or a placebo. The study is conducted at a research facility (not a long-term commitment) and is open to healthy adults. **You may be eligible if...** - You are between 18 and 50 years old - You have not used CBD or any cannabis product in the past 24 hours before the study visit **You may NOT be eligible if...** - You have difficulty seeing a computer screen - You have heart problems or heart disease - You have a neurological condition such as epilepsy, stroke, multiple sclerosis, a brain tumor, or a vascular abnormality - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCannabidiol Oral Product

Participants will receive a one-time dose of 600 mg Cannabidiol Isolate Gel Capsules in the form of six 100mg capsules.

OTHERPlacebo

Participants will receive a one-time dose of placebo capsules in the form of six capsules.


Locations(1)

University of Connecticut

Storrs, Connecticut, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05283382


Related Trials